PFC
TVTX icon

Phocas Financial Corp’s Travere Therapeutics TVTX Stock Holding History

Phocas Financial Corp’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-223,183
Closed -$3.43M – 185
2023
Q2 		$3.43M Sell
223,183
-1,080
-0.5% -$19.6K 0.47% 91
2023
Q1 		$5.04M Buy
224,263
+106,015
+90% +$2.25M 0.72% 58
2022
Q4 		$2.49M Sell
118,248
-123
-0.1% -$2.61K 0.36% 105
2022
Q3 		$2.92M Buy
+118,371
New +$3.06M 0.45% 94

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Phocas Financial Corp's TVTX Position: Q3 2023 in Review

Phocas Financial Corp sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 223,183 shares — an estimated $3.43M sold.

Phocas Financial Corp first reported a position in TVTX in Q3 2022 and held it in 4 quarters. The position peaked at $5.04M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • Phocas Financial Corp reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Phocas Financial Corp sold 223,183 Travere Therapeutics shares in Q3 2023, an estimated $3.43M.
  • Phocas Financial Corp first reported a position in Travere Therapeutics in Q3 2022 and held it in 4 quarters.
  • Phocas Financial Corp's Travere Therapeutics position peaked at $5.04M in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Phocas Financial Corp's 13F filing for Q3 2023, filed 10 Oct 2023.